Recognition for friend of Optimum Dr. Ruth McKernan at prestigious award ceremony

There was deserved recognition for Dr Ruth McKernan CBE, founder of the biotech AstronauTx, at one of the most prominent events in the life science calendar.

Dr McKernan won the Most Significant Contribution to the Mediscience Sector Award at the European Mediscience Awards on Thursday evening.

Optimum Strategic Communications proudly worked with AstronauTx to announce the closing of its £48 million Series A financing for Alzheimer’s disease therapies in October.

Ariceum Therapeutics to Present Outstanding New Preclinical Data at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024

Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, on Monday announced that it will be presenting a poster highlighting outstanding new preclinical data showing the efficacy of its somatostatin receptor 2 (SST2) antagonist, SS0110 (satoreotide), relative to SST2-targeting agonists, at this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held 8-11 June 2024 in Toronto, Canada.

The poster revealed that SST2 antagonist, 225Ac-SSO110 (satoreotide), is multiple times more potent than SST2 agonist, 225Ac-DOTATATE and that satoreotide demonstrated durable complete response in standard murine xenograft models of Small Cell Lung Cancer in animal models, versus tumor growth delay with 225Ac-DOTATATE.


Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics

Commit Biologics, a pioneer in the activation of the complement system to treat cancer and autoimmune disease, on Monday announced it will present a poster containing key data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics, held in Loutraki, Ancient Corinth, Greece, on June 11-16, 2024.

Amber Implants Completes Enrolment of First-In-Human Clinical Trial of its VCFix Spinal System

Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, on Tuesday announced that it has completed enrolment of its first-in-human clinical trial with its innovative VCFix Spinal System. The VCFix Spinal System is the first device that does not rely on bone cement for the treatment of vertebral compression fractures.

Climate resilient crops: Novo Nordisk Foundation and the Wellcome Trust award a grant of up to DKK 585 million to the ‘Ancient Environmental Genomics Initiative for Sustainability’

Harnessing environmental DNA (eDNA), a pioneering new research project sets out to transform future cropping systems and to develop resilient crops in the face of climate change. The Novo Nordisk Foundation on Wednesday announced it has awarded a grant of up to DKK 585 million over seven years, co-funded with the Wellcome Trust, to the Ancient Environmental Genomics Initiative for Sustainability (AEGIS).

Directed by renowned evolutionary geneticist Professor Eske Willerslev from the University of Copenhagen and University of Cambridge, AEGIS’s research will provide invaluable insights into past ecosystems, guiding the development of durable, sustainable food systems worldwide.

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit

Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, on Thursday announced that it has gained approval from the FDA for an Investigational Device Exemption (IDE) submission to begin enrolling patients into a pivotal study for aXess.

aXess is a restorative vascular access conduit that enables the creation of new, permanent, living vessels for hemodialysis vascular access, offering an improved dialysis patient experience and avoiding the frequent reinterventions and complications, such as infections, faced by many renal disease patients. This IDE approval marks a significant milestone in the Company’s clinical strategy in the US.

Resolution Therapeutics to Host Virtual Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D.

Resolution Therapeutics , a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease, on Thursday announced that it will host a virtual R&D webinar on Friday 28th June 2024 at 12.30 BST / 7.30 EDT for investors, analysts and media.

The event will feature an in-depth update on clinical data from the extended MATCH Phase 2 clinical study and provide insight on Resolution’s novel discovery platform for engineered macrophage cell therapy to enhance therapeutic efficacy in end-stage liver disease (ESLD). Poster presentations on these data were presented at the EASL Congress 2024, held in Milan between 5-8 June 2024.

To register for the webinar, please use the link.

One month until ON Helix!

Will we see you there? ON Helix is a great One Nucleus event which addresses key bio-innovation trends, generating discussions around the progress and future of the Life Science industry.

More information on how to register here.

Optimum is a proud supporter of ON events and is happy to share an exclusive 10% F&F discount. Please get in touch if you would like to use this or connect with the team there!


Who’s on the move this month?

Check out the latest moves in the life sciences sector with our monthly round-up of new funds and the biggest job changes, including analysts, bankers, and healthcare journalists.

That’s all folks! We hope you are enjoying Optimum’s weekly round-ups; subscribe today so you never miss an edition.